Research advances of nanoknife ablation combined with programmed death-1/programmed death ligand-1 in treatment of pancreatic cancer and relative immunological mechanisms
10.13929/j.issn.1672-8475.2020.10.012
- VernacularTitle: 纳米刀消融联合程序性死亡蛋白-1/程序性死亡蛋白配体-1治疗胰腺癌及其免疫学机制研究进展
- Author:
Jing LI
1
Author Information
1. Department of Radiology, The First Medical Center of Chinese PLA General Hospital
- Publication Type:Journal Article
- Keywords:
Catheter ablation;
Nanoknife;
Pancreatic neoplasms;
Programmed cell death 1 ligand 2 protein;
Programmed cell death 1 receptor
- From:
Chinese Journal of Interventional Imaging and Therapy
2020;17(10):628-631
- CountryChina
- Language:Chinese
-
Abstract:
Although the special tumor microenvironment of pancreatic cancer is not conducive to immunotherapy, nanoknife ablation can partial reverse immunosuppression, therefore is the only way of ablation for pancreatic cancer. Results of animal studies showed that the treatment of pancreatic cancer with nanoknife ablation combined with programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) might prolong the survival time. The research advances of the mechanisms of nanoknife ablation combined with PD-1/PD-L1 in treatment of pancreatic cancer and the relative immunological mechanisms were reviewed in this article.
